The two-part trial will first study three dose levels in 144 children from age 6 months to 11 years, the company said in a statement Thursday. Once an appropriate dose is established for each of three age groups, 4,500 more kids in the U.S. and Europe will be enrolled in the second part of the trial, which will look at safety tolerability and immunogenicity of the vaccine, the company said.
Two-thirds of ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.